Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 46 of 46

Filter Applied: MRI (Click to remove)

Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Utility of MRI in Spinal Arteriovenous Fistula
Neruol 79:25-30,15, Toossi, S.,et al, 2012

Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

Agreement Regarding Diagnosis of Transient Ischemic Attach Fairly Low Among Stroke-Trained Neurologists
Stroke 41:1367-1370, Castle,J., et al, 2010

Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison With Double-Dose Gadopentetate Dimeglumine
AJNR 31:1055-1058, Kim,E.S., et al, 2010

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009

Surgery Versus Non-Surgical Therapy for Carpal Tunnel Syndrome: A Randomised Parallel-Group Trial
Lancet 374:1074-1081, 1042, Jarvik,J.,et al, 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Rapid Assessment of Perfusion-Diffusion Mismatch
Stroke 39:75-81, Butcher,K.,et al, 2008

Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008

Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008

Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007

Magnetic Resonance Perfusion Diffusion Mismatch and Thrombolysis in Acute Ischaemic Stroke: A Systematic Review of the Evidence to Date
JNNP 78:485-491,443, Kane,I.,et al, 2007

MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows
Stroke 38:2640-2645, Schellinger,P.D.,et al, 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006

Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol
Stroke 36:602-606, Ribo,M., et al, 2005

Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1099-1100, 1100, Zivin,J.A., 2005

Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1098-1099,1100, Schellinger,P.D. &Fiebach,J.B., 2005

Sensitivity and Interrater Agreement of CT and Diffusion-Weighted MR Imaging in Hyperacute Stroke
AJNR 24:878-885, Saur,D.,et al, 2003

Reliability of Assessing Percentage of Diffusion-Perfusion Mismatch
Stroke 34:1681-1685, Coutts,S.B.,et al, 2003

Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia
Stroke 34:1907-1912, van Straaten,E.C.W.,et al, 2003

CT and Diffusion-Weighted MR Imaging in Randomized Order
Stroke 33:2206-2210,2144, Fiebach,J.B.,et al, 2002

Comparison of Diffusion-Weighted MRI and CT in Acute Stroke
Neurol 54:1557-1561,1548,1549,1552, Lansberg,M.G.,et al, 2000

Advantages of Adding Diffusion-Weighted Magnetic Resonance Imaging to Conventional Magnetic Resonance Imaging for Evaluating Acute Stroke
Arch Neurol 57:1311-1316, Lansberg,M.G. et al, 2000

Carotid Stenosis:A Comparison Between MR and Spiral CT Angiography
Neuroradiology 40:367-373, Magarelli,N.,et al, 1998

Improving Interobserver Variation in Reporting Gadolinium-Enhancing MRI Lesions in Multiple Sclerosis
Neurol 49:1682-1688, Barkhof,F.,et al, 1997

Intracranial Aneurysms:MR Angiographic Screening in 400 Asymptomatic Individuals with Increased Familial Risk
Radiology 195:35-40, Ronkainen,A.,et al, 1995

Blinded-Reader Comparison of MR & Duplex Ultrasonography for Carotid Artery Bifurcation Stenosis
Stroke 25:4-10, 11994., Mittl,R.L.,et al, 1994



Showing articles 0 to 46 of 46